EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

- February 26th, 2018

Emergent BioSolutions (NYSE: EBS) and Valneva announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1601, their vaccine candidate against Zika virus. As quoted in the press release: Adam Havey, Executive Vice President business operations at Emergent BioSolutions, said, “Emergent’s commitment to our mission – …

Emergent BioSolutions (NYSE: EBS) and Valneva announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1601, their vaccine candidate against Zika virus.

As quoted in the press release:

Adam Havey, Executive Vice President business operations at Emergent BioSolutions, said, “Emergent’s commitment to our mission – to protect and enhance life – fuels our pursuit for preparedness solutions against Zika virus, the consequences of which remain a public health challenge that requires attention. Our collaboration with Valneva on this Phase 1 study intends to make meaningful contributions to global research in this field.”

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply